Design Therapeutics, Inc. Logo

Design Therapeutics, Inc.

DSGN

(1.2)
Stock Price

6,72 USD

-18.74% ROA

-18.01% ROE

-5.51x PER

Market Cap.

278.572.860,00 USD

1.03% DER

0% Yield

-5701.55% NPM

Design Therapeutics, Inc. Stock Analysis

Design Therapeutics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Design Therapeutics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Design Therapeutics, Inc. Price Chart

Chart

Combination chart with 3 data series.
The chart has 2 X axes displaying Time, and navigator-x-axis.
The chart has 3 Y axes displaying values, values, and navigator-y-axis.
View 1 month1mView 3 months3mView 6 months6mView year to dateYTDView 1 year1yView allAllHighcharts.com
End of interactive chart.

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Design Therapeutics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0.89
Price to Earning Ratio
-5.51x
Price To Sales Ratio
332.43x
POCF Ratio
-5.45
PFCF Ratio
-5.41
Price to Book Ratio
1.07
EV to Sales
281.12
EV Over EBITDA
-3.74
EV to Operating CashFlow
-4.62
EV to FreeCashFlow
-4.58
Earnings Yield
-0.18
FreeCashFlow Yield
-0.18
Market Cap
0,28 Bil.
Enterprise Value
0,24 Bil.
Graham Number
9.64
Graham NetNet
4.49

Income Statement Metrics

Net Income per Share
-0.89
Income Quality
1.01
ROE
-0.18
Return On Assets
-0.18
Return On Capital Employed
-0.24
Net Income per EBT
1
EBT Per Ebit
0.79
Ebit per Revenue
-72.57
Effective Tax Rate
-0.05

Margins

Sales, General, & Administrative to Revenue
22.43
Research & Developement to Revenue
52.69
Stock Based Compensation to Revenue
14.83
Gross Profit Margin
0.48
Operating Profit Margin
-72.57
Pretax Profit Margin
-57.02
Net Profit Margin
-57.02

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.9
Free CashFlow per Share
-0.91
Capex to Operating CashFlow
-0.01
Capex to Revenue
0.52
Capex to Depreciation
0.77
Return on Invested Capital
-0.25
Return on Tangible Assets
-0.19
Days Sales Outstanding
608.91
Days Payables Outstanding
831.99
Days of Inventory on Hand
0
Receivables Turnover
0.6
Payables Turnover
0.44
Inventory Turnover
0
Capex per Share
0.01

Balance Sheet

Cash per Share
4,62
Book Value per Share
4,62
Tangible Book Value per Share
4.62
Shareholders Equity per Share
4.62
Interest Debt per Share
0.05
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
0.68
Current Ratio
41.42
Tangible Asset Value
0,26 Bil.
Net Current Asset Value
0,26 Bil.
Invested Capital
262758999
Working Capital
0,26 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Design Therapeutics, Inc. Profile

About Design Therapeutics, Inc.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

CEO
Mr. Pratik Shah Ph.D.
Employee
54
Address
6005 Hidden Valley Road
Carlsbad, 92011

Design Therapeutics, Inc. Executives & BODs

Design Therapeutics, Inc. Competitors

Monte Rosa Therapeutics, Inc. Logo
Monte Rosa Therapeutics, Inc.

GLUE

(1.2)
Werewolf Therapeutics, Inc. Logo
Werewolf Therapeutics, Inc.

HOWL

(1.2)
Ikena Oncology, Inc. Logo
Ikena Oncology, Inc.

IKNA

(1.2)
Stoke Therapeutics, Inc. Logo
Stoke Therapeutics, Inc.

STOK

(1.2)
Achilles Therapeutics plc Logo
Achilles Therapeutics plc

ACHL

(1.2)
Neoleukin Therapeutics, Inc. Logo
Neoleukin Therapeutics, Inc.

NLTX

(1.5)
Magenta Therapeutics, Inc. Logo
Magenta Therapeutics, Inc.

MGTA

(1.2)
Graphite Bio, Inc. Logo
Graphite Bio, Inc.

GRPH

(1.2)
ALX Oncology Holdings Inc. Logo
ALX Oncology Holdings Inc.

ALXO

(1.0)
Aadi Bioscience, Inc. Logo
Aadi Bioscience, Inc.

AADI

(1.2)
ADC Therapeutics SA Logo
ADC Therapeutics SA

ADCT

(1.2)
AlloVir, Inc. Logo
AlloVir, Inc.

ALVR

(1.2)
Gracell Biotechnologies Inc. Logo
Gracell Biotechnologies Inc.

GRCL

(1.0)
Theseus Pharmaceuticals, Inc. Logo
Theseus Pharmaceuticals, Inc.

THRX

(1.2)
Erasca, Inc. Logo
Erasca, Inc.

ERAS

(1.8)
Cullinan Oncology, Inc. Logo
Cullinan Oncology, Inc.

CGEM

(1.2)
Immunocore Holdings plc Logo
Immunocore Holdings plc

IMCR

(1.0)
C4 Therapeutics, Inc. Logo
C4 Therapeutics, Inc.

CCCC

(1.2)